What is the price change of platinib under the medical insurance policy?

Pralsetinib, an innovative drug targeting specific cancer types, is currently at a critical stage of review of health care policy. As a member of the tyrosine kinase inhibitor (TKI) family, platinib has been marketed as an original drug in China, but its position in the medical insurance list has yet to be determined. Therefore, its price after medical insurance is still unknown.

If Platinib can be successfully incorporated into the medical insurance system, its price is expected to be lower than the current market price, which will undoubtedly greatly reduce the financial burden on patients and families. According to the current market situation, the price of Platinib original drug 100mg*120 capsules per box is about RMB 60,000. However, this price is expected to be adjusted significantly once health insurance negotiations achieve positive results.

Platinib's main therapeutic area is for adult and pediatric patients with advanced or metastatic non-small cell lung cancer (NSCLC) and thyroid cancer who carryRET fusion gene mutations. RET gene mutation, as an oncogenic mutation that can promote the proliferation and spread of cancer cells, is the therapeutic target of Platinib. By precisely blocking the abnormally active RET protein kinase, Platinib can effectively inhibit the growth of cancer cells.

Compared with traditional chemotherapy methods, Platinib has demonstrated a more prominent therapeutic effect due to its precise targeting mechanism. Clinical data show that when dealing with advanced cancer caused by RET fusion gene mutations, platinib can significantly reduce tumor size, control its growth, and bring longer survival to patients. Nonetheless, the use of platinib is not without risks. Like all medications, it can cause a range of adverse effects. Therefore, before starting platinib treatment, patients need to provide detailed medical history information to the doctor and strictly follow the doctor's instructions for medication.